Goldenwell Biotech, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $55 | $139 | $1.8K | $47.8K | $16.0K | $0 | $0 |
| Cost of Revenue | $43 | $75 | $1.2K | $22.6K | $7.6K | $0 | $0 |
| Gross Profit | $12 | $64 | $666 | $25.2K | $8.4K | $0 | $0 |
| Gross Margin | 21.8% | 46.0% | 36.3% | 52.7% | 52.5% | — | — |
| Operating Expenses | |||||||
| Research & Development | — | — | — | — | — | — | — |
| SG&A Expense | $113.3K | $123.2K | $116.5K | $1.0M | $126.7K | $6.4K | $2.6K |
| Operating Income | $-113.3K | $-123.1K | $-115.8K | $-985.1K | $-118.3K | $-6.4K | $-2.6K |
| Operating Margin | -206,047.3% | -88,559.7% | -6,308.6% | -2,060.9% | -740.7% | — | — |
| Interest Expense | $8.4K | $8.4K | $1.5K | — | $0 | $0 | $0 |
| Pretax Income | — | $-131.5K | $-117.4K | — | $-118.3K | $-6.4K | $-2.6K |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-296.5K | $-131.5K | $-117.4K | $-985.1K | $-117.0K | $-6.3K | $-2.3K |
| Net Margin | -539,038.2% | -94,602.9% | -6,392.2% | -2,060.9% | -732.6% | — | — |
| EPS (Basic) | — | — | — | — | $0.00 | $0.00 | $0.00 |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | — | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | — | — | — | 99.0M | 91.5M | 91.5M | 80.0M |
| Shares Outstanding (Diluted) | 99.0M | 99.0M | 99.0M | 99.0M | 91.5M | 91.5M | 80.0M |
| Dividends Per Share | — | — | — | — | — | — | — |